Factors associated with recurrence and survival length following relapse in patients with neuroblastoma by Basta, NO et al.
Factors associated with recurrence and
survival length following relapse in patients
with neuroblastoma
Nermine O Basta1, Gail C Halliday2,3, Guy Makin4,5, Jillian Birch4, Richard Feltbower6, Nick Bown7,
Martin Elliott8, Lucas Moreno9, Giuseppe Barone9, Andrew DJ Pearson9, Peter W James1,
Deborah A Tweddle*,2,3 and Richard JQ McNally*,1
1Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK; 2Newcastle Cancer Centre at the Northern Institute
for Cancer Research, Newcastle University, Newcastle upon Tyne, UK; 3Department of Paediatric Oncology, The Great North
Children’s Hospital, Newcastle upon Tyne, UK; 4Institute of Cancer Sciences, Manchester Cancer Research Centre, Manchester
Academic Health Sciences Centre, University of Manchester, Manchester, UK; 5Department of Paediatric Oncology, Royal
Manchester Children’s Hospital, Manchester, UK; 6Division of Epidemiology and Biostatistics, School of Medicine, University of
Leeds, Leeds, UK; 7Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK; 8Paediatric Oncology and
Haematology Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK and 9Children and Young People’s Unit, The Royal
Marsden NHS Foundation Trust, Sutton, and Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer
Research, Sutton, UK
Background: Despite therapeutic advances, survival following relapse for neuroblastoma patients remains poor. We investigated
clinical and biological factors associated with length of progression-free and overall survival following relapse in UK
neuroblastoma patients.
Methods: All cases of relapsed neuroblastoma, diagnosed during 1990–2010, were identified from four Paediatric Oncology
principal treatment centres. Kaplan–Meier and Cox regression analyses were used to calculate post-relapse overall survival
(PROS), post-relapse progression-free survival (PRPFS) between relapse and further progression, and to investigate influencing
factors.
Results: One hundred eighty-nine cases were identified from case notes, 159 (84.0%) high risk and 17 (9.0%), unresectable,
MYCN non-amplified (non-MNA) intermediate risk (IR). For high-risk patients diagnosed42000, median PROS was 8.4 months
(interquartile range (IQR)¼ 3.0–17.4) and median PRPFS was 4.7 months (IQR¼ 2.1–7.1). For IR, unresectable non-MNA
patients, median PROS was 11.8 months (IQR 9.0–51.6) and 5-year PROS was 24% (95% CI 7–45%). MYCN amplified (MNA)
disease and bone marrow metastases at diagnosis were independently associated with worse PROS for high-risk cases.
Eighty percent of high-risk relapses occurred within 2 years of diagnosis compared with 50% of unresectable non-MNA IR
disease.
Conclusions: Patients with relapsed HR neuroblastomas should be treatment stratified according to MYCN status and PRPFS
should be the primary endpoint in early phase clinical trials. The failure to salvage the majority of IR neuroblastoma is concerning,
supporting investigation of intensification of upfront treatment regimens in this group to determine whether their use would
diminish likelihood of relapse.
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Neuroblastoma, the second most common childhood solid tumour,
accounts for 8% of all childhood (0–14 years) cancers in the United
Kingdom (Stiller, 2007). It is one of the most difficult childhood
cancers to cure with UK and Ireland 5-year survival of 64.7% for
cases diagnosed during 2005–2007 (Gatta et al, 2014).
However, survival remains poor for children diagnosed with
high-risk disease (50% of all neuroblastoma) (Cohn et al, 2009)
defined as stage 441 year of age, or MYCN amplified (MNA)
localised (stages 2 and 3) or MNA infant (o12 month) disease,
with relapse in 450% of cases (Maris et al, 2007; Maris, 2010).
Relapse also occurs in other risk groups including intermediate risk
(around 20% of cases at diagnosis) defined as MYCN non-
amplified (non-MNA), unresectable (stage 3) and non-MNA
stage 4 o12 months old cases. The presence of MNA is a well-
established poor prognostic marker in patients with neuroblastoma
with localized disease and infants o12 months of age (Cohn and
Tweddle, 2004; Maris et al, 2007; Canete et al, 2009). Survival from
relapsed high-risk neuroblastoma is currently o10% (London
et al, 2011; Park et al, 2013). The disease control intervals and the
patterns of recurrence are important for evaluation of new
treatment strategies and early phase study designs, as they are
increasingly being used to define alternative end-points to tumour
response (Santana et al, 2008; Fox et al, 2014).
Some recent studies have reported clinical features of relapsed
neuroblastoma (Garaventa et al, 2009; London et al, 2011; Simon
et al, 2011), however few report length of post-relapse progression-
free survival (PRPFS). The present study aimed to investigate
factors associated with recurrence, survival length following relapse
and length of progression-free survival in patients with neuro-
blastoma diagnosed and treated at four UK Paediatric Oncology
principal treatment centres. This study included information from
patient file review on PRPFS, which is essential for informing the
design and judging the efficacy of new treatments tested in early
phase clinical trials.
MATERIALS AND METHODS
Study patients. All cases of relapsed and refractory/progressive
neuroblastoma diagnosed during 1990–2010 were identified from
four UK Paediatric Oncology principal treatment centres
(The Royal Victoria Infirmary, Newcastle, Leeds Teaching
Hospitals NHS Trust, The Royal Manchester Children’s Hospital
and The Royal Marsden Hospital). Population-based data from
three specialist registries were used: the Northern Region Young
Persons’ Malignant Disease Registry (NRYPMDR) (Cotterill et al,
2000), the Yorkshire Specialist Register of Cancer in Children and
Young People (YSRCCYP) (Feltbower et al, 2004) and the
Manchester Children’s Tumour Registry (MCTR) (Birch, 1988),
and a non-population database held at the Royal Marsden Hospital
NHS Foundation Trust. All cases within the age ranges of the
registries were included. Year 1990 was chosen as the start date as
from this date onwards combination chemotherapy and high-dose
myeloablative therapy were routinely used to treat high-risk
neuroblastoma (Pritchard et al, 2005; Pearson et al, 2008). Nine
patients who died within 7 days of relapse were excluded as their
survival and treatment data at relapse would be limited.
Definition of relapse. The International Neuroblastoma Response
Classification (INRC) criteria were used to define relapse as a new
site of disease or 25% increase in tumour size following an initial
response (including partial) to treatment, and refractory disease as
tumours that did not respond to any first-, second- or third-line
therapies and subsequently progressed (Brodeur et al, 1993).
Statistical analysis. Table 1 and Supplementary Table S1 show the
demographic and clinical variables studied at diagnosis and
relapse. Post-relapse overall survival time (PROS) was the primary
end point, defined as time from first relapse/progression (including
relapsed refractory disease) to death or date of last follow-up in
survivors. Follow-up was censored at 31 March 2014. Kaplan–
Meier methods were used to calculate estimates of PROS and
PRPFS, which is the time between relapse and further relapse/
progression (Kaplan and Meier, 1958). Log-rank tests were used to
compare differences in survival estimates between variables.
Cox proportional hazards regression analysis was used to
investigate risk factors that may influence PROS (Cox, 1972).
The associations between PROS and MYCN amplification, 1p
deletion, time interval from diagnosis to relapse and age at
diagnosis were analysed. Age at diagnosis was categorised into
o18 months, X18 months and o5 years, X5 years, since 18
months is now used to stratify patients at diagnosis and there is
evidence that older children have a more protracted relapse course
(Cohn et al, 2009). Time interval from diagnosis to relapse was
categorised as o6 months, 6 to o12 months, 12 to o18 months,
18 to o24 months and X24 months to enable comparison with
previously published studies (London et al, 2011; Simon et al,
2011). Two time periods of diagnosis, p2000 and 42000, were
used to categorise patients as around this time treatment for high-
risk neuroblastoma was intensified (Kohler et al, 2007; Pearson
et al, 2008; Ladenstein et al, 2010; Kohler et al, 2013). Only models
that met the Cox proportional hazard assumption are presented
(Cox, 1972).
Subgroup analyses by risk group were carried out for high risk
and intermediate risk (IR) patients using the International
Neuroblastoma Risk Group (INRG) definitions and a comparison
of survivors vs non-survivors (Cohn et al, 2009). Detailed analysis
of unresectable, non-MNA cases was undertaken as this group has
varied clinical behaviour (Park et al, 2009; Baker et al, 2010).
Where the total number of cases was low, the 95% Wilson
confidence intervals for binomial percentages were calculated. Stata
version 12 was used for all analyses, with statistical significance
taken to be Po0.05 (StataCorp, 2011).
RESULTS
One hundred eighty-nine cases of relapsed neuroblastoma were
identified in this study. A flow diagram showing numbers of patients
by risk group is given in Figure 1. For all relapsed cases PROS
significantly increased after 2000 (Po0.001) (Supplementary Figure
S1a and Supplementary Figure S1b).
High-risk group. The number of cases analysed for each variable
differed depending on the completeness of available data (Table 1
and Supplementary Table S1). At diagnosis, 90% of cases were
treated in a clinical trial or per clinical trial protocol
(Supplementary Table S2). The overall response assessment
according to the INRC criteria (Brodeur et al, 1993) at the end
of first-line treatment was: partial response including very good
partial response for 70 out of 139 (50%) cases and complete
response for 30 out of 139 (22%) cases. At first relapse, 124 out of
159 (78%) of cases relapsed within 2 years of diagnosis and 13 out
of 107 (12%) of patients relapsed at the primary site alone. In 60
patients (38%) in whom levels of urinary catecholamines were
recorded at diagnosis and relapse, 48 (80%) had raised urinary
catecholamines levels at both diagnosis and relapse.
The median PROS time for all high-risk cases was 4.5 months
(interquartile range (IQR) 1.9–11.4), which was significantly
increased for patients diagnosed after 2000 vs before (Po0.001)
(Figure 2A and B, Supplementary Figure S2a and Supplementary
Figure S2b). Significantly more patients diagnosed after 2000, 60
out of 74 (81%), were treated actively at relapse compared with
those who were given palliative radiotherapy or supportive care
alone 14 out of 74 (19%); vs 22 out of 64 (44%)p2000) (P¼ 0.03).
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Active treatments at relapse included second-line chemotherapy,
mIBG therapy, or second-line chemotherapy followed by other
treatments such as radiotherapy, or phase I or II clinical trials in 10
out of 138 (7%) cases (Table 2). Figure 3 shows that for cases
diagnosed after 2000, 6 out of 76 (8%) patients treated by mIBG
therapy had a median PROS of 12.2 months (IQR¼ 10.9–26.2
months), 5 out of 76 (7%) patients enrolled onto phase I or II trials
had a median PROS of 13.5 months (IQR¼ 7.7–16.4) and 29 out of
76 (38%) treated by second-line chemotherapy had a median PROS
of 6.6 months (IQR¼ 2.5–17.5) compared with 1.5 months
(IQR¼ 0.6–2.9) for cases treated by supportive care (P¼ 0.01). In
contrast, before 2000 only one patient had mIBG therapy. For 58
cases, the date of further relapse/progression was recorded and for
those patients the median PRPFS was 4.5 months (IQR 2.2–8.7
months); it was 3.9 months (IQR 2.5–8.7 months) for 21 cases
diagnosed before 2000 and 4.7 months (IQR 2.1–7.1 months) for 37
cases diagnosed after 2000 (P¼ 0.54). Treatments received at
subsequent relapse/progression are given (Supplementary Table S3).
Cox univariable proportional hazards regression analyses for
high-risk cases showed that PROS time was significantly worse for
cases with MNA disease (Po0.0001), both MNA and 1p deleted
disease (P¼ 0.02), liver metastases at diagnosis (P¼ 0.02), and for
cases who relapsed within 6 months of diagnosis compared with
relapses42 years (P¼ 0.03), while patients45 years old at diagnosis
had longer PROS (P¼ 0.02) (Supplementary Table S4). However, in
multivariable analysis only MNA (adjusted HR¼ 2.06; 95%
CI 1.22–3.46, P¼ 0.007) and bone marrow metastases at diagnosis
(adjusted HR¼ 2.33; 95% CI 1.26–4.29, P¼ 0.007) were indepen-
dently significantly associated with worse PROS (Table 3). Informa-
tion on MYCN status was unknown for 30% of cases, so sensitivity
analysis was carried out to include the MYCN unknown cases as an
additional category in the model, which showed that it did not affect
the results. MNA disease was significantly associated with worse
PROS (Po0.001) (Figure 2C and Supplementary Figure S2c). Similar
results were obtained for PROS for cases diagnosed before (Po0.001)
(Figure 2D) or after 2000 (P¼ 0.02) (Figure 2E).
Intermediate risk, unresectable, MYCN non-amplified group.
The number of cases analysed for each variable differed depending
on the completeness of available data (Table 1 and Supplementary
Table 1. Patient characteristics at relapse for all cases of relapsed neuroblastoma, high-risk cases, and intermediate risk, stage 3,
unresectable, non-MNA cases
All relapsed
neuroblastoma
N¼189
N (%, 95% CI)b
High-risk relapsed
Neuroblastoma
N¼159 (84.1%)
N (%, 95% CI)b
Intermediate risk
(unresectable MYCN
non-amplified)
N¼17 (9.0%)
N (%, 95% CI)c
P-valuea
(high vs intermediate
risk groups)
Time from diagnosis to relapse
Mean 18.1 months 17.6 months 28.8 months
Median 14.7 months 14.6 months 22.1 months
Interquartile range 9.2–22.1 months 9.3–21.5 months 10.3–39.1 months 0.03
Range 1.3–96.2 months 1.3–96.2 months 4.0–68.5 months
Time from diagnosis to relapse groups
o6 months 32 (16.9, 11.9–23.1) 24 (15.1, 9.9–21.6) 1 (5.8, 1.0–27.0)
6–12 months 38 (20.1, 14.6–26.5) 32 (20.1, 14.2–27.2) 4 (23.5, 9.6–47.3) 0.23
12–18 months 43 (22.8, 17.0–29.3) 40 (25.2, 18.6–32.6) 2 (11.8, 3.3–34.3)
18–24 months 32 (16.9, 11.9–23.1) 28 (17.9, 12.0–24.4) 2 (11.8, 3.3–34.3)
424 months 44 (23.3, 17.5–30.0) 35 (22.0, 15.8–29.3) 8 (47.1, 26.2–69.0)
Site of relapse N¼132 (69.8)d N¼107 (67.3)d N¼13 (76.5)d
Primary 30 (22.7, 15.9–30.8) 13 (12.2, 6.6–19.9) 8 (61.5, 35.5–82.3)
Metastases 102 (77.3, 69.2–84.1) 94 (87.8, 80.1–93.4) 5 (38.5, 17.7–64.5) o0.001
Missing 57 (30.2)e 52 (32.7)e 4 (23.5)e
Bone metastases at relapse N¼170 (89.9)d N¼142 (75.1)d 15 (88.2)d
No 87 (51.2, 43.4–58.9) 70 (49.3, 40.8–57.8) 9 (60.0, 35.7–80.2)
Yes 83 (48.8, 41.1–56.6) 72 (50.7, 42.2–59.2) 6 (40.0, 19.8–64.3) 0.43
Missing 19 (10.1)e 17 (24.9)e 2 (11.8)e
Bone marrow metastasis at
relapse
N¼140 (74.1)d N¼116 (73.0)d N¼13 (76.5)d
No 75 (53.6, 45.0–62.0) 58 (50.0, 40.6–59.4) 9 (69.2, 42.4–87.3)
Yes 65 (46.4, 38.0–55.0) 58 (50.0, 40.6–59.4) 4 (30.8, 12.7–57.6) 0.24
Missing 49 (25.9)e 43 (27.0)e 4 (23.5)e
Urinary catecholamine levels
at relapse
N¼87 (46.0)d N¼73 (45.9)d N¼9 (52.9)d
Normal 20 (23.0, 14.6–33.2) 14 (19.2, 10.9–30.1) 6 (66.7, 35.4–87.9)
Elevated 67 (77.0, 66.8–85.4) 59 (80.8, 55.1–77.7) 3 (33.3, 12.1–64–6) 0.006
Missing 102 (54.0)e 86 (54.1)e 8 (47.1)e
Status
Alive 16 (8.5, 4.9–13.4) 5 (3.1, 1.0–7.2) 4 (23.5, 9.6–47.3)
Dead 166 (87.8, 82.3–92.1) 148 (93.1, 88.0–96.5) 13 (76.5, 52.7–90.4) 0.001
Lost to follow-up 7 (3.7, 1.5–7.5) 6 (3.8, 1.4–8.0) –
aChi-squared test and the Fisher’s exact test (where numbers were o5) were used to compare between high and intermediate risk group characteristics.
b95% CI were calculated for percentages using the asymptotic method.
c95% CI for proportions were calculated using the Wilson score method.
dPercent of the total number of cases.
ePercent with missing data.
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Table S1). The International Neuroblastoma Pathology Classifica-
tion (INPC) histology (Shimada et al, 1999) was unfavourable in 13
out of 15 (87%; 95% CI 62–96%) cases and primary tumour site
was abdominal in 14 out of 17 (82%; 95% CI 59–94%), 12 out of 17
(71%; 95% CI 47–87%) were treated in a clinical trial at diagnosis
or per clinical trial protocol (four cases in European Neuroblas-
toma Study group Fifth study (ENSG5) (Pearson et al, 2008), two
cases in European High Risk Neuroblastoma Study 1 of SIOP-
Europe (HRNBL1) (Ladenstein et al, 2010), two in unresectable
NB2009 (Kohler et al, 2013), four in ENSG9 (ClinicalTrials.gov
identifier: NCT00276731; Supplementary Table S2). At the end of
treatment 7 out of 15 (47%; 95% CI 25–70%) cases had achieved
partial response and 6 out of 15 (40%; 95% CI 20–64%) complete
response. The median PROS time for this group was 11.8 months
(IQR¼ 9.0–51.6) (Supplementary Figure S3a and b).
Significantly more cases relapsed 42 years from diagnosis 8
out of 17 (47%; 95% CI 26–69%) compared with high-risk cases
35 out of 159 (22%; 95% CI 16–29; P¼ 0.04). Eight out of thirteen
(62%; 95% CI 36–82%) relapsed at the primary site. In 9 out of 17
patients (53%, 31–74%) in whom levels of urinary catecholamines
were recorded at diagnosis and relapse, 3 out of 9 (33%; 95% CI 12–
65%) had raised urinary catecholamine levels at both diagnosis and
relapse. Eleven out of sixteen patients (69%; 95% CI 44–86%) were
treated with second-line high-risk type chemotherapy at first relapse
(Table 2). A further relapse/progression date and treatment were
recorded for eight cases, and for those the median PRPFS was 10.1
months (IQR¼ 7.8–12.3 months). Five out of eight (63%; 95% CI
31–86%) were treated with second line chemotherapy and the
remainder treated by combined chemotherapy and surgery or
radiotherapy including mIBG therapy or supportive care
(Supplementary Table S3).
Survivors. Only 8% of all relapsed patients in our study survived
to the end of the study period (Supplementary Table S5). Fifteen
All relapsed neuroblastoma
cases identified from four UK
Paediatric Oncology principal
treatment centres
N = 198
Cases that died within 7 days of diagnosis of
relapse were excluded from the study
N = 9
All relapsed neuroblastoma cases excluding
those who died within 7 days of diagnosis
of relapse
High-risk cases
N = 159
Died
N = 154
Survived
N = 5
Died
N = 3
Survived
N = 4
Died
N = 13
Survived
N = 4
Died
N = 1
Survived
N = 2
Stage 4, MYCN non-amplified
infants <12 months
N = 7
Unresectable, stage 3, MYCN non-
amplified
N = 17
Intermediate risk
N = 24 Low risk (stages 1, 2 and 4)
N = 3
Risk unknown
(stage unknown)
N = 3
Figure 1. Flow diagram showing number of cases included in the study.
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Figure 2. Kaplan–Meier graphs for post-relapse overall survival time for the high-risk group (N¼159). (A) Post relapse overall survival (PROS)
time. Median PROS time for high-risk cases was 4.5 months (IQR¼ 1.9–11.4). Five-year PROS for high-risk cases was 7.4% (95% CI 4.0–12.1%). (B)
Post-relapse overall survival by year of diagnosis. Median PROS time was 2.9 months (IQR 1.4–6.9) for cases diagnosedp2000 vs 8.4 months (IQR
3.0–17.4) for cases diagnosed42000 (Po0.001). Five-year PROS for high-risk cases diagnosedp2000 was 2.4% (95% CI 0.5–7.7%) vs 12.7% (95%
CI 6.4–21.2%) for cases diagnosed42000. (C) PROS byMYCN status. Median PROS time was 2.9 months (95% CI 2.0–4.3) forMYCN amplified vs
8.5 months for MYCN non-amplified (95% CI 5.9–11.1; Po0.001). Five-year PROS for MYCN non-amplified cases was 9.0% (95% CI 3.7–17.2%) vs
4.1% (95% CI 0.8–12.3%) for MYCN amplified cases. (D) PROS for cases diagnosed p2000 by MYCN status. For cases diagnosed p2000, the
median PROS for MYCN amplified disease was 1.5 months (95% CI 0.9–2.7) vs 5.1 months (95% CI 2.9–7.9) for MYCN non-amplified cases
(Po0.001). Five year PROS forMYCN non-amplified was 3.6% (95% CI 0.3–15.4%) vs 0% forMYCN amplified cases. (E) PROS for cases diagnosed
42000 by MYCN status. For cases diagnosed 42000, the median PROS for MYCN amplified disease was 4.3 months (95% CI 2.9–6.6) vs 10.9
months (95% CI 6.3–14.4) for MYCN non-amplified (P¼0.02). Five-year PROS for MYCN non-amplified cases was 12.8% (95% CI 4.7–25.2%) vs
7.7% (95% CI 1.3–21.7%) for MYCN amplified cases.
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out of sixteen patients (8%; 95% CI 72–99%) were disease free
5 years from first relapse. Four out of five of the high-risk survivors
and 1 out of 4 of the IR were diagnosed 42000. The median
follow-up time from relapse for survivors was 11 years (IQR 6.6–16.5).
Eight out of sixteen (50%; 95% CI 28–72%) patients were aged
p18 months at diagnosis, 5 out of 15 (33%; 95% CI 15–58%) had
high-risk disease at diagnosis and 12 out of 13 (85%; 95% CI 58–96%)
were non-MNA. At relapse, 8 out of 14 (57%; 95% CI 33–79%)
Table 2. Treatment received at first relapse for all relapsed neuroblastoma cases, high risk cases and intermediate risk, stage 3,
unresectable, non-MNA neuroblastoma
All relapsed cases N (%) High Risk N (%) Intermediate risk N (%)
Treatment
Diagnosed
p2000
Diagnosed
42000 Total
Diagnosed
p2000
Diagnosed
42000 Total
Diagnosed
p2000
Diagnosed
42000 Total
Second-line Chemotherapya 29 (36.3) 33 (38.4) 62 (37.4) 22 (34.4) 29 (39.2) 51 (37.0) 2 (22.2) 1 (14.3) 3 (18.8)
Combination of treatmentsb 15 (118.8) 17 (19.8) 32 (19.3) 10 (15.6) 12 (16.20 22 (15.9) 4 (44.4) 4 (57.1) 8 (50.0)
mIBG therapy 1 (1.3) 6 (7.0) 7 (4.2) 1 (1.6) 6 (8.1) 7 (5.1) 0 (0.0) 0 (0.0) 0 (0.0)
Other (e.g., surgery or
radiotherapy)
7 (8.8) 10 (11.6) 17 (10.2) 4 (6.3) 8 (10.8) 12 (8.7) 2 (22.2) 2 ( 28.6) 4 (25.0)
Phase I or II trials 5 (6.3) 5 (5.8) 10 (6.0) 5 (7.8) 5 (6.8) 10 (7.3) 0 (0.0) 0 (0.0) 0 (0.0)
Palliative radiotherapy 10 (12.5) 6 (7.0) 16 (9.6) 10 (15.6) 6 (8.1) 16 (11.6) 0 (0.0) 0 (0.0) 0 (0.0)
Supportive care 13 (16.3) 9 (10.5) 22 (13.3) 12 (18.8) 8 (10.8) 20 (14.5) 1 (11.1) 0 (0.0) 1 (6.3)
Total 80 (100) 86 (100) 166 (100) 64 (100) 74 (100) 138 (100) 9 (100) 7 (100) 16 (100)
aSecond-line chemotherapy includes vincristine, temozolamide, irinotecan, topotecan vincristine-doxorubicin or oral etoposide.
bCombination of chemotherapy, surgery, radiotherapy and miBG therapy.
High risk relapsed neuroblastoma cases (N = 159)
Cases diagnosed  2000 (N = 82)
Median PRPFS
in months (IQR)
6.7 (3.5 – 29.5)
Second line
chemotherapy
Combination of
treatments
mIBG therapy
Other
treatment
Phase I or II
trials
Palliative
radiotherapy
Supportive
care
Median PROS
in months (IQR)
Median PROS
in months (IQR)
Cases diagnosed > 2000 (N = 76)
Median PRPFS
in months (IQR)
Treatments at
relapse
N = 7
3.8 (2.1 – 9.7)
N = 22
4.4 (2.0 – 7.5)
N = 10
6.6 (2.5 – 17.5)
N = 29
8.5 (4.3 – 12.3)
N = 12
12.2 (10.9 – 26.2)
N = 6
11.3 (5.9 – 37.9)
N = 8
3.2 (1.6 – 6.2)
N = 4
13.5 (7.7 – 16.4)
N = 5
4.7 (2.6 – 10.6)
N = 4
6.5 (3.2 – 8.8)
N = 4
6.1 (2.6 – 7.1)
N = 7
2.1 (1.3 – 2.2)
N = 16
8.6 (4.2 – 13.3)
N = 6
1.5 (0.6 – 2.9)
N = 8 N < 3
N < 3
– –
4.9 (2.8 – 8.7)
N = 5
N < 3 N < 3
– –
N < 3 N = 4
4.2 (1.8 – 6.9)
N = 5
5.1 (4.2 – 22.6)
N = 3
1.7 (1.4 – 16.0)
N = 3
3.4 (2.2 – 5.1)
N = 10
2.1 (1.9 – 4.7)
N = 12N < 3
– – 0.9 (0.4 – 1.7)
– –
Figure 3. Flow diagram showing treatments that high-risk patients received at first relapse and its outcome. Abbreviations: PROS ¼ post-
relapse overall survival; IQR ¼ interquartile range; PRPFS ¼ post-relapse progression-free survival.
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survivors were treated with second-line chemotherapy, and/or with
radiotherapy and surgery and 1 out of 14 was treated with
chemotherapy and autologous stem cell transplant.
Comparing survivors with non-survivors showed that 27%
(95% CI 11–52%) of survivors had favourable INPC histology
compared with 4% (95% CI 1–8%) of non-survivors (P¼ 0.006),
93% (95% CI 70–99%) of survivors had complete or partial overall
response at end of treatment compared with 71% of non-survivors
(95% CI 64–79%; P¼ 0.04), and 50% relapsed 42 years from
diagnosis compared with 21% (95% CI 15–28%) of non-survivors
(P¼ 0.01) (Supplementary Table S6). Of the high-risk survivors, 3
out of 5 were X18 months at diagnosis, 4 out of 5 relapsed after
initial myeloablative therapy and 1 out of 5 relapsed after surgery.
DISCUSSION
This study was designed to gain knowledge about relapsed
neuroblastoma from primary sources of information and to reflect
the outcome of these patients, avoiding the selection bias of clinical
trials. It is the first multi-institutional study to report on PRPFS
which is a very useful parameter for judging the efficacy of early
phase clinical trials. The observed interval between relapses is
important for early phase trials design as it provides a baseline
comparator for exploratory studies of new agents in relapsed
neuroblastoma, where the time interval of PRPFS can be used as a
primary endpoint when designing exploratory trials (Santana et al,
2008; Fox et al, 2014).
The current study reports the demographics of relapsed
neuroblastoma cases diagnosed during 1990–2010 from four UK
Paediatric Oncology principal treatment centres treating around
30% of all UK patients in total. PROS time remains very poor for
both high risk and IR (unresectable, non-MNA) disease. The
median PROS for high-risk cases was 4.5 months with only 7% of
relapsed cases surviving more than 5 years. However, PROS has
significantly increased for high-risk cases diagnosed after the year
2000 compared with before 2000 from 2.9 months to 8.4 months,
achieving a 5-year survival of 12.7%. This significant improvement
in PROS after 2000 may be due to more patients being treated
actively at relapse with second line chemotherapy such as
temozolomide, topotecan, irinotecan or oral etoposide. All these
chemotherapy regimens increase the PRPFS, but long-term overall
survival remains poor (Rubie et al, 2006; London et al, 2010;
Bagatell et al, 2011; Fox et al, 2014).
High risk. In contrast to most previous epidemiological studies of
relapsed neuroblastoma, our study reports second relapses. The
duration from first to subsequent relapse is important particularly
for early phase clinical trial design. For a sub-group of patients, the
date of a second event was recorded and the median PRPFS time to
second event was 4.5 months (IQR¼ 2.2–8.7). This is shorter than
that reported by Santana and colleagues, who found a median
disease progression-free interval of 7.2 months between first and
second relapse (Santana et al, 2008). This may reflect a difference
in treatments given, as very few patients in our cohort were treated
on phase I or II clinical trials at first or subsequent relapse, partly
due to a lack of available applicable trials before 2000 (Moreno
et al, 2013). Recently trials for relapsed neuroblastoma have
opened across Europe, such as the BEACON study, a randomised
phase II trial exploring the use of bevacizumab and temozolomide
or temozolomide-irinotecan (ClinicalTrials.gov identifier:
NCT02308527). The results of our study demonstrating the very
poor outcomes following relapse strongly argue for the inclusion of
patients with high risk relapsed neuroblastoma in randomised
clinical trials at relapse whenever possible. This study does not
identify a specific group of patients who are less likely to benefit
from further treatment at relapse.
Our results for PROS concur with those published using data
from the INRG database (2226 relapsed cases), diagnosed during
1990–2002, where 5-year PROS for stage 4 cases, 418 months
with non-MNA disease was 8%, and only 4% for stage 4 with MNA
disease (London et al, 2011). Around 55 out of 189 (29%) cases
from the present study may overlap with the INRG database.
A study from the Italian neuroblastoma registry reported 10-year
PROS for stage 4 disease at diagnosis was 1.5% following
progression and 2% following relapse (Garaventa et al, 2009).
Analysis of relapsed high-risk neuroblastoma patients from
German trials diagnosed during1990–2007, treated with second-
line chemotherapy at relapse, found 3-year PROS was 9.6% (Simon
et al, 2011).
Several prognostic factors are used in risk stratification for
neuroblastoma at diagnosis including age at diagnosis, MNA, presence
of segmental chromosomal aberrations, metastatic disease and tumour
histology (George et al, 2001). These factors may also be important in
determining response to treatments at relapse. Age 45 years at
Table 3. Results of multivariable analysis for post-relapse overall survival for high-risk cases
Factor N (%) Hazard ratio (95% CI) P-value
Age at diagnosis
p5 years 126 (79.3) 1
45 years 33 (20.7) 0.77 (0.44–1.34) 0.35
Bone marrow metastases at diagnosis
No 26 (17.8) 1
Yes 120 (82.2) 2.33 (1.26–4.29) 0.007
Liver metastases at diagnosis
No 122 (87.8) 1
Yes 17 (12.2) 1.44 (0.73–2.83) 0.29
MYCN disease
Not amplified 67 (57.8) 1
Amplified 49 (42.2) 2.06 (1.22–3.46) 0.007
Time from diagnosis to relapse
424 months 35 (22.0) 1
18–24 months 28 (17.9) 1.18 (0.58–2.40) 0.65
12–18 months 40 (25.2) 1.21 (0.65–2.24) 0.54
6–12 months 32 (20.1) 1.22 (0.65–2.31) 0.54
o6 months 24 (15.1) 1.52 (0.76–3.01) 0.24
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diagnosis had a longer PROS consistent with studies showing that older
children have a more protracted relapse course (Cohn et al, 2009). We
also found worse PROS in high-risk cases withMYCN amplification as
previously reported (Lau et al, 2004; Garaventa et al, 2009; London
et al, 2011; Simon et al, 2011), and with both MNA and chromosome
1p deletion at diagnosis. Chromosome 1p deletion has been shown
to be associated with shorter median PROS (Lau et al, 2004; London
et al, 2011), poorer event-free survival from diagnosis (EFS)
(Maris et al, 2001), and to be strongly related to high-risk features
(Attiyeh et al, 2005). Both 1p deletion and 11q loss were independently
associated with shorter PRPFS in patients with low and IR disease
(Attiyeh et al, 2005). However, in the present study insufficient data on
11q or other segmental chromosomal abnormalities precluded formal
analysis. Interestingly, liver metastases at diagnosis were also associated
with shorter PROS in our study. In previous studies, liver metastases
were associated with MNA and had a worse prognosis in older children
(DuBois et al, 1999), unlike infants with non-MNA disease (Kushner
et al, 2006). Ninety percent of all relapsed cases we studied had primary
tumours arising in abdominal sites and only 8% had thoracic or neck
tumours. This is in-keeping with other studies reporting that adrenal
tumours are associated with unfavourable clinical and biological
characteristics and therefore worse EFS in contrast to thoracic tumours
which are associated with favourable characteristics and better EFS
(Sung et al, 2009; Vo et al, 2014). However, we acknowledge the small
numbers of cases involved in this study and the missing data in some of
the variables means some results should be interpreted with caution.
The duration from diagnosis to first relapse has been shown to
be a prognostic factor for PROS (Lau et al, 2004; Garaventa et al,
2009; London et al, 2011). Around 80% of high-risk cases in our
study relapsed within 2 years from diagnosis, and PROS was
significantly shorter when relapse occurred within 6 months of
diagnosis. Lau and colleagues found that patients who relapsed
either within 6 months from diagnosis or 6 months from stem cell
transplant had shorter median PROS (Lau et al, 2004). Other
studies, however, reported recurrence within 6–24 months from
diagnosis implied worse PROS (London et al, 2011; Simon et al,
2011). These differences may be due to patient heterogeneity; some
studies included only high-risk cases (Simon et al, 2011), whereas
others included all relapsed neuroblastoma (London et al, 2011), or
different definitions of relapse.
The role of urinary catecholamines as a reliable marker for
monitoring neuroblastoma relapse is controversial (Simon et al,
2003). They may be negative due to small tumour burden at relapse
or decreased production in some previously treated neuroblasto-
mas. In the present study, urinary catecholamines were raised at
relapse in 80% of patients who had raised catecholamines at
diagnosis, but were only measured in 46% of patients at relapse.
The current study suggests that raised urinary catecholamines are
helpful as a confirmatory indicator and a tumour marker of
response (Kushner et al, 2009).
Intermediate risk. IR disease comprised 13% of relapsed neuro-
blastomas in our study, 4% who were IR stage 4, non-MNA o12
months old were not further analysed as this subgroup is usually
salvageable at relapse (Maris et al, 2007; De Bernardi et al, 2009).
However, 9% were IR, unresectable, non-MNA with mostly
unfavourable INPC histology. The prognostic value of pathology
in this group was confirmed in a recent SIOPEN study (Kohler
et al, 2013). Analysis of stage 3 data from the INRG database
showed that patients 418 months with undifferentiated INPC
histology and elevated levels of serum ferritin had worse overall
survival and EFS (Meany et al, 2014). In the absence of MYCN
amplification other genetic markers in this group may be important
risk factors, such as tumour cell ploidy (Bagatell et al, 2005;
Baker et al, 2010), 11q aberrations (Attiyeh et al, 2005; Meany et al,
2014) or other segmental chromosomal abnormalities (Defferrari
et al, 2015). The management of this group of patients remains
controversial, those with unfavourable histological or biological
features are treated with intensive multimodality therapy including
myeloablative therapy in the United States (Baker et al, 2010), but not
in the United Kingdom or Europe. However, in the present study
6 out of 17 patients (35%; 95% CI 17–59%) were treated in high-risk
protocols (ENSG5 and HRNBL1) at the physician’s discretion due to
patient age and/or unknown MYCN status. Almost 50% of IR,
unresectable, non-MNA neuroblastoma relapsed 42 years from
diagnosis including 5 out of 17 (29%; 95% CI 13–53%) patients who
had local radiotherapy as part of their frontline treatment at diagnosis.
Salvage therapies at relapse failed in 75% of cases, suggesting the need
for intensification of upfront treatment regimens for cases with
unfavourable histology at diagnosis (Kohler et al, 2013), to determine
whether their use would diminish the likelihood of relapse.
CONCLUSION
In conclusion, this study showed that the PROS for neuroblastoma
patients has increased but long-term survival remains poor. Eighty
percent of high-risk relapses occur within 2 years from diagnosis,
in contrast to only 50% of IR unresectable, non-MNA neuro-
blastoma, and although this latter group comprise o10% of all
relapsed neuroblastoma, the failure to salvage these patients in over
75% of cases, even when given high-risk-type treatment at relapse,
is concerning. Since MNA disease has a worse OS as highlighted by
previous studies, our study underscores the need for early phase
clinical trial data to be analysed according to MYCN status. Finally,
more patients need to be recruited to early phase studies where
PRPFS should be considered as the primary endpoint in study
design, especially if cytostatic novel therapies are given.
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